Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Sheinelle Jones will cohost fourth hour of 'Today' with Jenna Bush Hager: Here's what to know about her - 2CRP Subsea secures contract for Vattenfall’s Nordlicht I cable systems
- 3Hyundai Is Keeping the i30 Alive While America Keeps Losing Cars Like It
- 4Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- 5The Iran war’s energy security legacy
- Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest
- Iran's stolen futures: The arrested Iranians at risk of execution by the regime
- Qatar LNG Ships U-Turn After Attempt to Pass Through Hormuz
- New movies to watch this weekend: See 'Predator: Badlands' in theaters, rent 'Black Phone 2,' stream Guillermo del Toro's 'Frankenstein' on Netflix
- Why some African countries are prone to military takeovers
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- The most effective method to Pick The Right Speakers
- Instructions to Pick the Right Senior Protection Plan.
- Best Streaming Gadget for Your Home Theater
